To what extent can our intestinal microbiota predict the risk of developing diseases? In the case of multifactorial diseases, bacterial taxa alone do not provide much information, according to a study ...
TechBio company MultiOmic Health (MOH) initially set out to build an artificial intelligence (AI)-enabled platform to research metabolic dysfunction-associated conditions. In just three years, not ...
PALO ALTO, Calif., May 1, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to ...
Speakers at the Institute for Value-Based Medicine event held September 18, 2025, in Nyack, New York, spoke about methods of managing cardio-renal-metabolic disease ...
PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DEDThis FDA-aligned trial targets ...
BUFFALO, NY — January 20, 2026 — A new review was published in Volume 17, Issue 12 of Aging-US on December 30, 2025, titled “Aging as a multifactorial disorder with two stages.” “This article is a ...
Interview has been edited for readability. AJMC®: What percentage of your practice is dedicated to treating dry eye disease (DED), and has this changed over time? Devries: Approximately 90% of my ...
—A recent study highlights the importance of differentiating familial chylomicronemia syndrome (FCS) from multifactorial chylomicronemia syndrome (MCS) for setting expectations, guiding genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results